Traders should monitor for FDA feedback ahead of the December 2026 PDUFA date; any safety concerns or delays could trigger volatility. Positive momentum supports long positioning ahead of decision, but risks remain around approval and commercial uptake.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $28.43entry
- T+1 · 8mo ago −1.62%α −1.51% · $27.97
- T+5 · 8mo ago −11.99%α −11.09% · $25.02
- T+20 · 7mo ago −2.36%α −2.20% · $27.76
- T+60 · 6mo ago −11.85%α −23.54% · $25.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hypertension, and set a PDUFA action date of December 22, 2026. While the Phase 2 Explore-OSA trial missed its primary endpoint of reducing apnea-hypopnea index in sleep apnea patients, it showed clinically meaningful blood pressure reduction and a favorable safety profile, supporting the drug's potential in resistant hypertension.
Key Facts
- FDA accepted NDA for lorundrostat with PDUFA date of December 22, 2026
- Lorundrostat demonstrated 6.2 mmHg placebo-adjusted systolic BP reduction in Explore-OSA trial (p < 0.0003)
- Primary endpoint (AHI reduction) in Explore-OSA trial was not met
- Drug showed favorable safety profile with no serum potassium excursions above 5.5 mmol/L
- NDA supported by positive Phase 3 Launch-HTN and Phase 2 Advance-HTN trials
Financial Impact
Potential blockbuster approval in 2026 for a $219B U.S. hypertension market with high unmet need
Risk Factors
- FDA may require additional data or delay approval despite acceptance
- Failure in Explore-OSA primary endpoint may raise questions about broader indications
- Commercial success depends on differentiation from existing antihypertensives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252329 |
Track record
35 reports on MLYS
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers